Amgen says its cholesterol shot prevented heart problems in a broad population

Amgen's cholesterol-lowering drug, Repatha, demonstrated prevention of heart disease death, heart attack, and stroke in a 12,000-patient trial, a finding expected to significantly broaden its market. This positive outcome signals a potential commercial resurgence for PCSK9 inhibitors, a class of drugs that initially underperformed. With Repatha's global sales reaching $2.2 billion in 2024, up 36% year-over-year, analysts see substantial growth opportunity given its low single-digit market penetration despite a vast addressable patient population.

Analysis

Amgen's Repatha has demonstrated a significant clinical breakthrough in a 12,000-patient trial, proving its ability to prevent a composite of heart disease death, heart attacks, and strokes. This positive outcome is poised to broaden the drug's market access and represents a pivotal moment for the entire PCSK9 inhibitor class, which had previously faced commercial challenges. Financially, Repatha is already exhibiting strong momentum, with global sales reaching $2.2 billion in 2024, a 36% year-over-year increase. The primary growth opportunity, as highlighted by Leerink Partners, lies not in expanding the patient pool but in increasing treatment rates within the vast, undertreated population. With current market penetration reported to be in the low single digits, these trial results provide Amgen with a powerful tool to drive a greater sense of urgency among clinicians, suggesting a substantial runway for future revenue acceleration.

Key Decisions for Investors

• The positive trial data for Repatha acts as a major catalyst, supporting a bullish outlook on Amgen's near-to-medium term revenue growth, as it directly addresses prior commercial hurdles.
• Investors should closely monitor Repatha's market penetration and prescription rates, as any acceleration from the current low single-digit level would be a strong indicator of the drug's trajectory toward blockbuster status.
• Given the drug's substantial addressable market and now-strengthened clinical profile, it is prudent to re-evaluate long-term earnings models for Amgen, factoring in potentially higher and more durable sales for Repatha.